Objective
The current study aims to evaluate the utility of impression cytology in the diagnosis of ocular surface alterations in multiple sclerosis patients as well as to connect impression cytology results with symptoms and clinical evaluation data.
Patients and Methods:
The study included 60 patients [120 eyes] who were divided into 3 groups: Group 1: included 20 participants (40 eyes) with early-diagnosed multiple sclerosis; group 2: included 20 participants (40 eyes) with multiple sclerosis who are already receiving treatment; and group 3: included 20 participants (40 eyes) who were randomly assigned to an age-matched control group who had no ocular or systemic pathologies. In people aged 20 to 40, an ocular tear film was evaluated. All patients finished the routine ophthalmological assessment, fluorescein tear breakup time [TBUT], Schirmer test, and conjunctival impression cytology [CIC].
Results
Most of the early group patients showed grades 1, 2 and 3 (20%, 35% and 30% respectively) in CIC results in 85% of the eyes, whilst in the chronic group patients showed grades 1, 2 and 3 (35%, 25%and 15% respectively) in CIC results in 75% of the eyes, while in the control subjects, impression cytology results showed that all cases were grade 0 (100%) with a highly statistically significant difference with P-value < 0.001. As regarding the mean scores for the TBUT and Schirmer scores for the control group patients, they were (13.7 ± 1.488s) and (13.325 ± 1.5424mm), respectively, whilst the mean scores for the TBUT and Schirmer scores for the early group patients were (7.85 ± 2.1068s) and (7.525 ± 1.9347mm), respectively, while the mean scores for the TBUT and Schirmer scores for the chronic group patients were (9.625 ± 3.3258s) and (9.8 ± 3.4877mm) with a highly statistically significant difference with a P-value < 0.001.
Conclusion
Impression cytology is a non-invasive procedure for examining ocular surface cell morphology that can be used to identify and assess the severity of conjunctival alterations in people with multiple sclerosis.